<scp>LncRNA PVT1</scp> promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells-Reference-Cited by-同舟云学术

LncRNA PVT1 promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells

Published:2023-08-02 Issue:9 Volume:37 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Wang Lu¹²^ORCID,Yang Guang³^ORCID,Guo Pengyu¹^ORCID,Lv Yulin¹^ORCID,Fu Bo¹^ORCID,Bai Yang¹^ORCID,Xiong Feng²^ORCID,Zhao Danfeng¹^ORCID,Li Cong¹^ORCID,Zhang Jianji¹^ORCID,Bai Shiyu¹^ORCID,Zeng Fanshu¹^ORCID,Xu Wanhai¹²^ORCID

Affiliation:

1. NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy Harbin Medical University Harbin China

2. Department of Urology (Heilongjiang Key Laboratory of Scientific Research in Urology) The Fourth Hospital of Harbin Medical University Harbin China

3. Department of Neurosurgery The First Affiliated Hospital of Harbin Medical University Harbin China

Abstract

AbstractRenal cancer stem cells (RCSCs) derived from clear cell renal cell carcinoma (ccRCC) tissues with higher microvessel density (MVD) have strong stemness and endothelial progenitor cells‐like (EPCs‐like) characteristics. A high level of lncRNA PVT1 expression is essential for simultaneously retaining strong RCSC stemness and EPCs‐like characteristics. PVT1 binds with TAZ protein and prevents its phosphorylation, which promotes RCSC stemness. Moreover, RCSCs support endothelial differentiation and angiogenesis, which are mediated via the PVT1/miR‐15b/KDR axis. This report provides insight into the determinants of RCSC impact on stemness and highlights the critical role of RCSC in angiogenesis. The presented findings suggest that targeting RCSC through PVT1 expression may be a new treatment strategy for ccRCC.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Reference31 articles.

1. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update

2. Treatment of renal cell carcinoma: Current status and future directions

3. MCPIP1 Downregulation in Clear Cell Renal Cell Carcinoma Promotes Vascularization and Metastatic Progression

4. Benefits of pazopanib over sunitinib for renal cell carcinoma

5. Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI